Microcap Ledger ImageneBio, Inc. $IMA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- Shares outstanding
- 11,351,456 [10-Q 2026-08-05]
What the company doesAI summary of filing
ImageneBio, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for immunological, autoimmune and inflammatory diseases. The company's lead asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody in clinical development for atopic dermatitis and potentially other indications. IMG-007 is not yet approved or generating revenue; the company is currently advancing a Phase 2b dose-finding study expected to report topline data in 2027 and has completed four earlier-stage clinical trials. The company generates no revenue and expects to incur significant losses for the foreseeable future. [10-K 2026-03-10]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$20.80M | −$23.87M | $94.68M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | $800.0K | −$45.35M | −$47.84M | $94.53M | [10-K 2026-03-10] |
| FY ended Dec 2024 | $3.50M | −$36.57M | −$21.32M | $12.12M | [10-K 2026-03-10] |
- Quarterly cash burn
- −$11.94M
- Cash runway Estimate
- ~23.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-08-01 | 48,258,111 | [10-Q 2024-08-08] |
| 2024-11-01 | 48,258,111 | [10-Q 2024-11-07] |
| 2025-02-28 | 48,258,111 | [10-K 2025-03-06] |
| 2025-05-01 | 48,258,111 | [10-Q 2025-05-08] |
| 2025-06-30 | 48,258,111 | [10-Q 2025-07-24] |
| 2025-11-03 | 11,181,672 | [10-Q 2025-11-12] |
| 2026-04-30 | 11,279,130 | [10-Q 2026-05-07] |
| 2026-07-31 | 11,351,456 | [10-Q 2026-08-05] |
- Shelf registration
- S-3 filed 2026-08-05; declared effective 2026-08-11 [S-3 2026-08-05]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | Yarema Kristin | grant | 254,800 | — | [4 2026-08-17] |
| 2026-08-14 | Grant-Huerta Yanina | grant | 65,000 | — | [4 2026-08-17] |
| 2026-08-14 | Grant-Huerta Yanina | grant | 39,000 | — | [4 2026-08-17] |
| 2026-07-25 | Yarema Kristin | exercise | 38,376 | — | [4 2026-07-28] |
| 2026-07-25 | Yarema Kristin | other | 115,129 | — | [4 2026-07-28] |
| 2026-07-17 | Lally Robert B | sell | 1,525 | $5.34 | [4 2026-07-20] |
| 2026-07-16 | Lally Robert B | sell | 1,671 | $5.50 | [4 2026-07-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-05 | S-3 | Registration statement |
| 2026-08-05 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-05 | S-3 | Registration statement |
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations |
| 2026-07-23 | 424B3 | Prospectus or prospectus supplement |
| 2026-07-23 | 8-K | Director or officer change; Other events |
| 2026-06-29 | 424B3 | Prospectus or prospectus supplement |
| 2026-06-26 | 8-K | Director or officer change |
| 2026-06-17 | 424B3 | Prospectus or prospectus supplement |
| 2026-06-17 | 8-K | Director or officer change; Shareholder vote results |
Alerts for $IMA
Email me when ImageneBio, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.